Durvalumab
Brand Names: Imfinzi
Methodology & AI Transparency ⓘ
Durvalumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a federal NDC-monographed programmed death ligand-1 blocker (0310-4611, 0310-4500, manufactured/labeled by AstraZeneca Pharmaceuticals LP), Durvalumab provides intravenous-route dosing across 500 mg/10mL Injection, Solution and 120 mg/2.4mL Injection, Solution under licensed medical supervision.
- 2 Real-world patient consensus: Real-world cohort score of 94% across 10 de-identified Durvalumab entries.
- 3 Typical cash cost range: Public pharmacy ledger: $86.67 low cash benchmark vs. $212.34 chain retail average ($1.9300/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Durvalumab: nausea (8.6%), headache (7.1%), dizziness (5.1%).
Ask our AI Specialists anything about Durvalumab
Durvalumab Mechanism, CYP450 Pathways & DailyMed Monograph
As a federal NDC-monographed programmed death ligand-1 blocker (0310-4611, 0310-4500, manufactured/labeled by AstraZeneca Pharmaceuticals LP), Durvalumab provides intravenous-route dosing across 500 mg/10mL Injection, Solution and 120 mg/2.4mL Injection, Solution under licensed medical supervision.
Acting as a intravenous-route programmed death ligand-1 blocker moiety, Durvalumab (NDC 0310-4611, 0310-4500, manufactured/labeled by AstraZeneca Pharmaceuticals LP) regulates downstream signaling pathways proportional to 500 mg/10mL Injection, Solution and 120 mg/2.4mL Injection, Solution titration and patient renal/hepatic reserve.
With Elimination kinetics span 8 to 16 hours per Durvalumab clinical pharmacology residence kinetics and Complete (~100%) parenteral systemic delivery for Durvalumab (500 mg/10mL Injection, Solution) bioavailability, Durvalumab undergoes systemic clearance of durvalumab integrates hepatic phase ii conjugation with renal filtration and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after durvalumab administration.
Standard adult regimens span 500 mg/10mL Injection, Solution, 120 mg/2.4mL Injection, Solution. Prescribers screen specifically against history of severe allergic sensitivity to durvalumab active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-07-01 durvalumab labeling, while community micro-logs most frequently note nausea (8.6% of reports), headache (7.1% of reports), fatigue (5.4% of reports).
Verify medication reconciliation lists so Durvalumab is not inadvertently duplicated with another programmed death ligand-1 blocker.
Botanical enzyme modulators may alter oral first-pass exposure of Durvalumab; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Durvalumab active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-07-01 Durvalumab labeling
Logged Side-Effect Incidence (10 Reports)
Durvalumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Durvalumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Immune-mediated side effects in the randomized phase 3 TOPAZ-1 study of: What a 338-Participant Study Found Durvalumab demonstrated an OS benefit versus placebo in aBTC, irrespective of imAEs, which were mostly low grade and manageable. The oncologist • 2025-07-04 • Phase III Randomized Trial | N = 338 | 93/100 | PMID 40622010 ↗ |
| New Insights on Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer:: What a 268-Participant Study Found These findings support the use of durvalumab plus EP as first-line standard of care for ES-SCLC. Clinical lung cancer • 2025-12-15 • Phase III Randomized Trial | N = 268 | 87/100 | PMID 40887341 ↗ |
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine and exposure-response analysis of These results support the novel perioperative durvalumab regimen for patients with resectable NSCLC from the AEGEAN study, and no dose adjustment is necessary based on the PopPK and ER analyses. British journal of clinical pharmacology • 2026-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41222125 ↗ |
| Can This Approach Help? Inside the Latest Research on NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients NEPTUNE did not meet its primary end point of improved OS with durvalumab plus tremelimumab versus chemotherapy in patients with mNSCLC and bTMB greater than or equal to 20 mut/Mb. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2023-01-15 • Phase III Randomized Trial | N = 69 | 82/100 | PMID 36240972 ↗ |
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine and Exposure-response Analysis of At 1500 mg IV Q4W, a flat E-R relationship was observed between durvalumab PK exposure and safety endpoints including Grade 3 + treatment-related AEs, Grade 3 + treatment-related AEs of special interest, and AEs leading to... The AAPS journal • 2026-09-28 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42806195 ↗ |
Durvalumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.9300/unit (~$57.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $212.34 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $86.67 / mo | View logs ↓ |
Durvalumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Durvalumab RxNorm Concept ID | RXN-03104611-2881 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.9300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $212.34 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $86.67 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Durvalumab Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Durvalumab integrating DailyMed SPL (2026-07-01), CMS NADAC ($1.9300/unit), and 10 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Durvalumab community threads and patient logs by age, biological sex, dosage, and treatment duration.